Glutathione inhalation - Renovion

Drug Profile

Glutathione inhalation - Renovion

Alternative Names: Arina-1; Inhaled L-glutathione - Renovion

Latest Information Update: 04 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of North Carolina at Chapel Hill
  • Developer Renovion
  • Class Antineoplastics; Chemoprotectants; Oligopeptides
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lung disorders
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Asthma; Cystic fibrosis; Lung disorders

Most Recent Events

  • 24 Jul 2017 Duke University plans a phase I trial for Lung disorders (lung dysfunction following lung transplant) in USA (NCT03226431)
  • 06 Jan 2017 Glutathione inhalation - Renovion receives Orphan Drug status for Lung disorders (lung dysfunction following lung transplant) in USA
  • 01 Feb 2016 Renovion receives patent allowance for glutathione inhalation in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top